|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | The use of poly(styrene-block-isobutyleneblock-styrene)as a microshunt to treat glaucoma显示文摘The InnFocus MicroShuntVR is a minimally invasive glaucoma drainage microtube used to shunt aqueous humor from the anterior chamber of the eye to a flap formed under the conjunctiva and Tenon’s capsule.The safety and clinical performance of this device approaches that of trabeculectomy with mitomycin C,the current‘gold standard’treatment for advanced glaucoma.The invention of a new biomaterial called poly(styrene-block-isobutylene-block-styrene)or‘SIBS’is the enabling factor which led to the success of this product.SIBS is ultrastable with virtually no foreign body reaction in the body,which manifests as clinically insignificant inflammation and capsule formation in the eye.The lack of capsule formation enables unobstructed flow through the 70 mm lumen tube and the achievement of controlled low intraocular pressure,which is important for the management of glaucoma.This article summarizes the integration of SIBS into a glaucoma drainage device and confirms its functionality with clinical success over a 2-year period. | Leonard Pinchuk Isabelle Riss Juan F.Batlle Yasushi P.Kato John B.Martin Esdras Arrieta Paul Palmberg Richard K.Parrish Bruce A.Weber Yongmoon Kwon Jean-Marie Parel | 2016 | Regenerative Biomaterials2016，3，2： | 5 |
| 2 | Microstructure and mechanical properties of Ti-6Al-4V-5% hydroxyapatite composite fabricated using electron beam powder bed fusion显示文摘A novel, Ti-6 Al-4 V(Ti64)/Hydroxyapatite(HA at 5% by weight concentration) metal/ceramic composite has been fabricated using electron beam powder bed fusion(EPBF) additive manufacturing(AM): specifically, the commercial electron beam melting(EBM?) process. In addition to solid Ti64 and Ti64/5% HA samples, four different unit cell(model) open-cellular mesh structures for the Ti64/5% HA composite were fabricated having densities ranging from 0.68 to 1.12 g/cm^3, and corresponding Young's moduli ranging from 2.9 to 8.0 GPa, and compressive strengths ranging from ~3 to 11 MPa. The solid Ti64/5%HA composite exhibited an optimal tensile strength of 123 MPa, and elongation of 5.5% in contrast to a maximum compressive strength of 875 MPa. Both the solid composite and mesh samples deformed primarily by brittle deformation, with the mesh samples exhibiting erratic, brittle crushing. Solid, EPBF-fabricated Ti64 samples had a Vickers microindentation hardness of 4.1 GPa while the Ti64/5%HA solid composite exhibited a Vickers microindentation hardness of 6.8 GPa. The lowest density Ti64/5%HA composite mesh strut sections had a Vickers microindentation hardness of 7.1 GPa. Optical metallography(OM) and scanning electron microscopy(SEM) analysis showed the HA dispersoids to be highly segregated along domain or grain boundaries, but homogeneously distributed along alpha(hcp) platelet boundaries within these domains in the Ti64 matrix for both the solid and mesh composites. The alpha platelet width varied from ~5 μm in the EPBF-fabricated Ti64 to ~1.1 m for the Ti64/5%HA mesh strut. The precursor HA powder diameter averaged 5 μm, in contrast to the dispersed HA particle diameters in the Ti64/5%HA composite which averaged 0.5 m. This work highlights the use of EPBF AM as a novel process for fabrication of a true composite structure, consisting of a Ti64 matrix and interspersed and exposed HA domains, which to the authors' knowledge has not been reported before. The results also illustrate the prospects not only for fabricating specialized, novel composite bone replacement scaffolds and implants, through the combination of Ti64 and HA, but also prospects for producing a variety of related metal/ceramic composites using EPBF AM. | César A.Terrazas Lawrence E.Murr Diego Bermudez Edel Arrieta David A.Roberson Ryan B.Wicker | 2019 | Journal of Materials Science & Technology2019，35，2： | 4 |
| 3 | Association of Nutrition Parameters Including Bioelectrical Impedance and Systemic Inflammatory Response With Quality of Life and Prognosis in Patients With Advanced Non-Small-Cell Lung Cancer: A Prospective Study显示文摘 | Karla Sánchez-Lara JennyG Turcott Eva Juárez Patricia Guevara Carolina Nú?ez-Valencia LuisF. O?ate-Oca?a Diana Flores Oscar Arrieta | 2012 | Nutrition and Cancer2012，，4： | 3 |
| 4 | Phylogeny and subgeneric classification of Bouteloua with a new species,B. herrera-arrietae (Poaceae: Chloridoideae: Cynodonteae: Boutelouinae)显示文摘Bouteloua (Poaceae:Chloridoideae:Cynodonteae;Boutelouiane ) 牧草草的一个重要的类正在包含在北墨西哥与差异的一个中心首先在美洲发现的 60 种类。一个现代 subgeneric 分类正在缺乏。我们的学习的目标是重建在用有与以前的研究相比的增加的种类采样的分子的数据的 Bouteloua 的种类之中的进化历史。种系发生的分析在 209 件样品, 59 种类(206 个个人) 在 Bouteloua 是上被进行,用二质体(rpl32-trnL 分隔符和 rps16-trnK 分隔符) 并且原子它的 1 &2 (ribosomal 内部抄录分隔符) 推断进化关系并且生产一个 subgeneric 分类的序列。总的来说,它的 and 质体发展史显示了类似的模式。然而, ITS 发展史缺乏脊梁结构,恢复仅仅从九的四内部 clades 在质体发展史发现。它的网络显示出一个放射的进化模式并且显示很多个不兼容的裂口,经过在不同的节的种类之间的杂交建议。从联合质体和它的区域的最大可能性的的树很好被决定并且描绘包括十强烈支持的 clades 和一中等支持的 clade 的强烈支持的 monophyletic Bouteloua。分子的结果在 Bouteloua s.l 以内支持 10 节和二个分部的识别;三节是新的:Barbata, Hirsuta,和 Trifida;四节是新联合:Buchloe, Cyclostachya, Opizia,和 Triplathera;并且二个分部是新的:Eriopoda 和 Hirsuta。基于我们的分子的结果和我们描述的独特词法人物的拥有从 Nuevo León 的新种, Bouteloua herrera-arrietae。 | Paul M. Peterson Konstantin Romaschenko Yolanda Herrera Arrieta | 2015 | Journal of Systematics and Evolution2015，53，4： | 2 |
| 5 | Optimizing the evolution of strength for lime-stabilized rammed soil显示文摘In the present study,unconfined compressive strength(qu)values of two lime-treated soils(soil 1 and 2)with curing times of 28 d,90 d and 360 d were optimized.The influence of void/lime ratio was represented by the porosity/volumetric lime content ratio(η/Liv)as the main parameter.η/Liv represents the volume of void influenced by compaction effort and lime volume.The evolution of qu was analyzed for each soil using the coefficient of determination as the optimization parameter.Aiming at providing adjustments to the mechanical resistance values,the η/Liv parameter was modified to η/LivC using the adjustment exponent C(to make qu-η/Liv variation rates compatible).The results show that with the decrease of η/LivC.qu increases potentially and the optimized values of C were 0.14-0.18.The mechanical resistance data show similar trends between qu and η/LivC for the studied silty soil-ground lime mixtures,which were cured at ambient temperature(23±2)℃ with different curing times of 28-360 d.Finally,optimized equations were presented using the normalized strengths and the proposed optimization model,which show 6% error and 95% acceptability on average. | Jair de Jesus Arrieta Baldovino Ronaldo Luis dos Santos Izzo Eclesielter Batista Moreira Juliana Lundgren Rose | 2019 | Journal of Rock Mechanics and Geotechnical Engineering2019，11，4： | 2 |
| 6 | Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial显示文摘 | Edward B Garon Tudor-Eliade Ciuleanu Oscar Arrieta Kumar Prabhash Konstantinos N Syrigos Tuncay Goksel Keunchil Park Vera Gorbunova Ruben Dario Kowalyszyn Joanna Pikiel Grzegorz Czyzewicz Sergey V Orlov Conrad R Lewanski Michael Thomas Paolo Bidoli Shaker | 2014 | The Lancet2014，，： | 2 |
| 7 | The global TRUST study of erlotinib in advanced non-small-cell lung cancer (NSCLC)显示文摘 | Groen H Arrieta O G Riska H | 2008 | J Clin Oncol2008，26，： | 1 |
| 8 | Primate lens capsule elasticity assessed using atomic force microscopy显示文摘 | Ziebarth N M Arrieta Esdras Feuer W J | 2011 | Experimental Eye Research2011，92，： | 1 |
| 9 | Association of nutritional status and serum albumin levels with development of toxicity in patients with advanced non-small cell lung cancer treated with paclitaxel-eisplatin chemotherapy: a prospective study显示文摘 | ARRIETA O MICHEL ORM VILLANUEVA-RODRIGUEZ G | 2010 | BMC Cancer2010，10，： | 1 |
| 10 | Antiproliferative effect of thalidomide alone and combined with carmusitine against C6 rat glioma显示文摘 | Arrieta O Guevara P Tamarize J | 2002 | Int J Exp Pathol2002，83，2： | 1 |
| 11 | Antiproliferative effect of thalidomide alone and combined with carmustine against C6 rat glioma显示文摘 | Arrieta O Guevara P Tamariz J | | 0，，： | 1 |
| 12 | Tumour necrosis factor alpha and troponin T as predictors of poor prognosis in patients with stable heart failure 显示文摘 | Rodriguez-Reyna TS Arrieta O Castilo - Martinez L | 2005 | Clin Invest Med2005，28，1： | 1 |
| 13 | Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer:a randomized,double-blind phaseⅢtrial显示文摘 | de Boer RH Arrietaó Yang CH | 2011 | J Clin Oncol2011，29，8： | 1 |
| 14 | Optimal design of aircraft structures with damage tolerance requirements 显示文摘 | ARRIETA A J STRIZ A G | 2005 | Struct Multidisc Optim2005，30，2： | 1 |
| 15 | A randomized, double-blind, phase m trial of ramucirumab, a VEGFR-2 monoclonal antibody, plus Docetaxel versus placebo plus Docetaxel for second-line treatment of non-small cell lung cancer 显示文摘 | Ciuleanu TE Arrieta O Prabhash K | 2014 | J Clin Oucol2014，32，15： | 1 |
| 16 | Plasma excit- atory amino acids in autism 显示文摘 | Moreno-Fuenmayor H Borjas L Arrieta A | 1996 | Invest Clin1996，37，2： | 1 |
| 17 | Blockage of angiotensin Ⅱ type 1 receptor decreases the synthesis of growth factors and induces apoptosis in C6 cultured cells and C6 rat glioma显示文摘 | Arrieta O Guevara P Escobar E | 2005 | Br J Cancer2005，92，7： | 1 |
| 18 | Induction of a hypercoagulability state and endothelial cell activation by granulocyte colony -stimulating factor in peripheral blood stem cell donors 显示文摘 | Canales MA Arrieta R Gomez- Rioja R etal | 2002 | J Hematother Stem Cell Res2002，11，： | 1 |
| 19 | Vandetanib plus pem-etrexed versus pemetrexed as second-line therapy in patientswith advanced non-small cell lung cancer(NSCLC):A random-ized,double-blind phase III trial(ZEAL)显示文摘 | De Boer R Arrieta O Gottfried M | 2009 | J Clin Oncol2009，2715，： | 1 |
| 20 | Con- current chemo-radiotherapy following neoadjuvant chemotherapy in locally advanced breast cancer显示文摘 | Alvarado-Mirandal A Arrieta O Gamboa-Vignolle C | 2009 | Radiat Oncol2009，4，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员